Search Within

Eric J Sherman

  1. "Endocrinology"
Formats
  1. Journal Article (27)
  2. Meeting Abstract (21)
  3. Book Section (1)
  4. Guidelines (1)
Groups
  1. Department of Medicine (50)
  2. Division of Subspecialty Medicine (50)
  3. Endocrinology (50)
  4. Head and Neck Service (50)
  5. Solid Tumor Oncology Division (50)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (35)

More Groups

People
  1. James Fagin (35)
  2. Robert Tuttle (33)
  3. Ronald Ghossein (27)
  4. Alan Ho (23)
  5. David Pfister (19)
  6. Ashok Shaha (15)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (1)
  4. 2022 (10)
  5. 2021 (2)
  6. 2020 (6)

More Years

Publications
  1. Journal of Clinical Oncology (12)
  2. Thyroid (7)
  3. International Journal of Radiation Oncology, Biology, Physics (5)
  4. Cancer (4)
  5. Cancer Research (2)
  6. Journal of Surgical Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (13)
  2. Wiley Blackwell (8)
  3. Mary Ann Liebert, Inc (7)
  4. American Association for Cancer Research (5)
  5. Elsevier Inc. (5)
  6. Nature Publishing Group (2)

More Publishers

Results (50)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas
    Meeting Abstract

    Montero-Conde, C.; Ruiz-Llorente, S.; Domínguez, J. M.; Knauf, J. A.; Viale, A.; Sherman, E. J.; Ryder, M.; Ghossein, R. A.; Rosen, N.; Fagin, J. A.
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma
    Journal Article

    Sherman, E. J.; Su, Y. B.; Lyall, A.; Schoder, H.; Fury, M. G.; Ghossein, R. A.; Haque, S.; Lisa, D.; Shaha, A. R.; Tuttle, R. M.; more...
    Thyroid (2013)

    Fulltext@MSK | Save
  • Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF -mutant thyroid carcinomas
    Journal Article

    Montero-Conde, C.; Ruiz-Llorente, S.; Domínguez, J. M.; Knauf, J. A.; Viale, A.; Sherman, E. J.; Ryder, M.; Ghossein, R. A.; Rosen, N.; Fagin, J. A.
    Cancer Discovery (2013)

    Fulltext@MSK | Save
  • Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer
    Journal Article

    Ho, A. L.; Grewal, R. K.; Leboeuf, R.; Sherman, E. J.; Pfister, D. G.; Deandreis, D.; Pentlow, K. S.; Zanzonico, P. B.; Haque, S.; Gavane, S.; more...
    New England Journal of Medicine (2013)

    Fulltext@MSK | Save
  • A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma
    Meeting Abstract

    Sherman, E. J.; Ho, A. L.; Fury, M. G.; Baxi, S. S.; Haque, S.; Korte, S. H.; Smith-Marrone, S.; Xiao, H.; Ghossein, R. A.; Fagin, J. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Reacquisition of RAI uptake in RAI-refractory metastatic thyroid cancers by pretreatment with the MEK inhibitor selumetinib
    Meeting Abstract

    Ho, A. L.; Leboeuf, R.; Grewal, R. K.; Sherman, E. J.; Deandreis, D.; Pentlow, K. S.; Tuttle, R. M.; Fury, M. G.; Ricarte-Filho, J. C. M.; Pfister, D. G.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • External beam radiation therapy in advanced or recurrent nonanaplastic thyroid cancer: An updated experience
    Meeting Abstract

    Romesser, P.; Riaz, N.; Lian, M.; Shaha, A.; Wong, R.; Sherman, E.; Sabra, M.; Tuttle, M.; Rao, S.; Lee, N. Y.
    International Journal of Radiation Oncology, Biology, Physics (2012)

    Fulltext@MSK | Save
  • A phase II study of VEGF trap in patients with radioactive iodine (RAI)-refractory thyroid carcinoma
    Meeting Abstract

    Sherman, E. J.; Ho, A. L.; Haque, S.; Tuttle, R. M.; Ghossein, R. A.; Schöder, H.; Baum, M. S.; Kelly, K.; Chen, A. P.; Shaha, A. R.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A phase II study of VEGF trap (aflibercept) in patients with radioactive iodine-refractory, positron emission tomography (PET) positive thyroid carcinoma
    Meeting Abstract

    Sherman, E. J.; Ho, A. L.; Haque, S.; Ghossein, R. A.; Lisa, D. M.; Schoder, H.; Baum, M. S.; Shaha, A. R.; Tuttle, R. M.; Pfister, D. G.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma
    Meeting Abstract

    Sherman, E. J.; Fury, M. G.; Tuttle, R. M.; Ghossein, R.; Stambuk, H.; Baum, M.; Lisa, D.; Su, Y. B.; Shaha, A.; Pfister, D. G.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save